US 12,171,747 B2
Material and method for treating cancer
Yulia Hionidi, Petah Tiqwa (IL); Omer Tsipori, Sha'ar Efraim (IL); and Marina Konorty, Hertzeliya (IL)
Assigned to UROGEN PHARMA LTD., Ra'anana (IL)
Filed by UROGEN PHARMA LTD., Ra'anana (IL)
Filed on Dec. 11, 2023, as Appl. No. 18/535,108.
Application 18/535,108 is a continuation of application No. 17/546,204, filed on Dec. 9, 2021.
Claims priority of provisional application 63/124,111, filed on Dec. 11, 2020.
Prior Publication US 2024/0108603 A1, Apr. 4, 2024
Int. Cl. A61K 31/407 (2006.01); A61K 9/06 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/38 (2006.01)
CPC A61K 31/407 (2013.01) [A61K 9/06 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 47/38 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A method for treating urinary tract cancer, the method comprising:
administering a pharmaceutical composition into an internal body cavity of the urinary tract of a subject in need thereof,
wherein the pharmaceutical composition comprises (b) reconstituted in (a),
wherein (a) is a biocompatible thermoreversible hydrogel comprising
from about 15% to about 35% (w/w) of Poloxamer 407 based on a total weight of the biocompatible thermoreversible hydrogel,
from about 0.01% to about 0.3% (w/w) of hydroxypropylmethylcellulose based on a total weight of the biocompatible thermoreversible hydrogel, and
water,
wherein (b) is a therapeutically effective amount of a lyophilized pharmaceutical composition comprising mitomycin C and a bulking agent,
wherein the bulking agent is urea,
wherein mitomycin C and the bulking agent are present in a ratio of from about 1:7 to about 1:9 in the lyophilized pharmaceutical composition, and
wherein mitomycin C is present in the pharmaceutical composition in a concentration of about 1.33 mg/ml to about 4 mg/ml.